Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1′, a series of selective TNF-α converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-α release

Journal of Medicinal Chemistry

Volumn 44, Issue 21, 2001, Pages 3351-3354

  Xue, C B ^a   He, X ^a   Corbett, R L ^a   Roderick, J ^a   Wasserman, Z R ^a   Liu, R Q ^a   Jaffee, B D ^b   Covington, M B ^a   Qian, M ^a   Trzaskos, J M ^a   Newton, R C ^a   Magolda, R L ^c   Wexler, R R ^a   Decicco, C P ^a  

^a DUPONT COMPANY   (United States)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIPHENYL DERIVATIVE; BIPHENYLMETHYL DERIVATIVE; HYDROXAMIC ACID; INFLIXIMAB; MACROCYCLIC COMPOUND; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CYTOKINE PRODUCTION; DRUG DESIGN; DRUG POTENCY; DRUG SELECTIVITY; ENZYME INHIBITION; IMMUNOREGULATION; NONHUMAN; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; SWINE;

ADAM PROTEINS; BINDING SITES; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; HYDROXAMIC ACIDS; LIPOPOLYSACCHARIDES; METALLOENDOPEPTIDASES; MODELS, MOLECULAR; PROTEASE INHIBITORS; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035846068     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0155502     Document Type: Article

References (21)

1. Human tumour necrosis factor: Production, purification and characterization
2. A metalloproteinase disintegrin that releases tumour necrosis factor-α from cells
3. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α
4. Taming TNF: Strategies to restrain this proinflammatory cytokine
5. Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis
6. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein
7. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing
8. The therapeutic potential of small molecule TACE inhibitors
9. Crystal structure of the catalytic domain of human tumor necrosis factorα-converting enzyme
10. Regulation of tumour necrosis factor-α by a metalloproteinase inhibitor
11. Processing of tumour necrosis factor-α precursor by metalloproteinases
12. Recent advances in matrix metalloproteinase inhibitors research
13. New drugs on the horizon: Matrix metalloproteinase inhibitors
14. Design, synthesis and structure-activity relationships of macrocyclic hydroxamic acids that inhibit TNF-α release in vitro and in vivo
15. Crystal structure of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors
16. Inhibition of stromelysin (MMP-3) by P1′-biphenylylethyl carboxyalkyl dipeptides
17. Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors